Fundz Deep Dive
Everything you need to win ExoCoBio — in one platform.
Who to reach, what to say, and why now on ExoCoBio — plus every funding round, exec hire, and M&A move that follows, each with the verified contact and the outreach written for you.
Get the full Deep Dive on ExoCoBio — free.
One free Deep Dive, emailed to you. No spam; unsubscribe anytime.
Ready now? Choose your plan · Request a demo · Sign in
Engage writes the reply
Grounded in signals no one else has — tuned to their persona.
Signals no one else has
UCC liens, benefit plans, 13F holdings, permits, exec moves — fused.
Verified contact + click-to-call
The decision-maker’s email and mobile — dial in-browser.
Exocobio, A Leader In Exosome Technology, Completes The Acquisition Of Benev, A Global Medical Aesthetic Brand
PRIVATEJul 12, 2023•almost 3 years ago
Acquiring Company
ExoCoBio
Acquired Company
BENEV Company
BiotechnologyManufacturingBiotechnologyHealth CareMedical
Description
ExoCoBio, a global leader in exosome-based regenerative aesthetics, is pleased to announce that they have completed the acquisition of a majority ownership in BENEV, a global medical aesthetic company based in the U.S.
M&A Insights
Based on deal dataIntegration timeline
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed